Assessing the efficiency of SBA-15 as a nanocarrier for diphtheria anatoxin

• Published in: Microporous and mesoporous materials 2021-01, Vol.312, p.110763, Article 110763
• Main Authors: Rasmussen, Martin Kjærulf, Bordallo, Heloisa N., Bordenalli, Marcela Aparecida, Akamatsu, Milena Apetito, Trezena, Aryene Góes, Tino-De-Franco, Milene, Sant'Anna, Osvaldo A., da Silva Martins, Tereza, de Souza Lopes, José Luiz, de Abreu Fantini, Márcia Carvalho, Pinto Oliveira, Cristiano Luis
• Format: Article
• Language: English
• Subjects: Diphtheria anatoxin; Oral vaccine; Ordered mesoporous silica
• ISSN: 1387-1811; 1873-3093
• DOI: 10.1016/j.micromeso.2020.110763

SBA-15 ordered mesoporous silica can be considered a promising inorganic nanocarrier with emerging potential as an oral vaccine adjuvant. In this study, we investigated its application in the encapsulation of the diphtheria anatoxin (dANA). We observed a considerable preservation of dANA secondary and tertiary structures, even after the drying process by means of Circular Dichroism (CD) and fluorescence spectroscopies. Antigen loading was assessed at a number of different ratios of adjuvant-to-antigen using a combination of nitrogen adsorption porosimetry and Small Angle X-ray Scattering (SAXS). Our data showed that the mass ratio of 1:10 (dANA:SBA-15) is recommended for total encapsulation of dANA in the mesopores, considering that at this relative mass concentration antigen clustering was avoided, which is deleterious effect for immunization purposes. dANA release in mimetic intestine fluid, at a pH equal to 6.8, was followed by in-situ SAXS measurements and shown to be slow, being more pronounced after 6 h and continuous up to 35 h. Finally, the immunogenic complex was tested in isogenic Balb C mice by oral and subcutaneous immunization routes, including a comparison with the only permitted adjuvant for human use, aluminum hydroxide. A higher antibody titer was obtained by subcutaneous and oral administration routes using SBA-15 as the vehicle of dANA, compared with the conventional aluminum hydroxide, demonstrating the viability to use this ordered mesoporous silica in the formulation of oral vaccines, as already proved for the Virus Like Particles (VLP) Hepatitis B (HBsAg) case. [Display omitted] •Successful incorporation of dANA in SBA15 mesostructure.•Controlled release of dANA into mimetic intestine fluid.•Optimized antibody titer when compared to conventional vaccination routes.